Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained an $85 price target.

May 08, 2024 | 9:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham maintains a Buy rating and an $85 price target on Apellis Pharmaceuticals.
The reiteration of a Buy rating and maintenance of an $85 price target by a reputable analyst like Joseph Stringer from Needham is likely to instill confidence among investors and could positively influence Apellis Pharmaceuticals' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100